These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19034277)

  • 1. Population screening for colorectal cancer: the implications of an ageing population.
    Macafee DA; Waller M; Whynes DK; Moss S; Scholefield JH
    Br J Cancer; 2008 Dec; 99(12):1991-2000. PubMed ID: 19034277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
    Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
    J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-stratified intensive follow up for treated colorectal cancer - realistic and cost saving?
    Macafee DA; Whynes DK; Scholefield JH
    Colorectal Dis; 2008 Mar; 10(3):222-30. PubMed ID: 17645572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60-69 years.
    Lee D; Muston D; Sweet A; Cunningham C; Slater A; Lock K
    Appl Health Econ Health Policy; 2010; 8(3):141-54. PubMed ID: 20369905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.
    Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC
    Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
    Lansdorp-Vogelaar I; van Ballegooijen M; Zauber AG; Habbema JD; Kuipers EJ
    J Natl Cancer Inst; 2009 Oct; 101(20):1412-22. PubMed ID: 19779203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of family history-based colorectal cancer screening in Australia.
    Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA
    BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.
    Sweet A; Lee D; Gairy K; Phiri D; Reason T; Lock K
    Appl Health Econ Health Policy; 2011; 9(1):51-64. PubMed ID: 21174482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of colorectal cancer screening in the average risk population.
    Leshno M; Halpern Z; Arber N
    Health Care Manag Sci; 2003 Aug; 6(3):165-74. PubMed ID: 12943152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance.
    Subramanian S; Bobashev G; Morris RJ
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1971-8. PubMed ID: 19567507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.